Generally speaking, the incretin effect is reduced or absent in type 2 diabetes (Fig. 1) because of the impaired insulinotropic action of endogenously secreted GIP, as can be inferred from the reduced insulinotropic activity of exogenously administered GIP (Fig. 2) [22–24, 63]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.